Zoetis Inc. (ZTS) SEC Filings & Earnings Calls

Leadership transition risk is low given orderly departure and experienced successor

“Departure not due to disagreement; Saccaro has CFO experience at GE HealthCare and Baxter”

U.S. companion animal revenue decline

“U.S. companion animal revenue declined 11% YoY, with dermatology down 16%.”

Restructuring execution risk

“Restructuring charges increased to $77M from $30M YoY, primarily for employee termination costs.”

IRS tax audit exposure

“IRS proposed adjustment of ~$450M for 2018 tax year; company is appealing.”

Companion animal demand pressure from macro-driven price sensitivity and competition

“lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories” · word for word

Generic competition impacting key brands Cerenia and Convenia

“impact of generic competition on the Cerenia and Convenia brands” · word for word

Tariff and Trade Policy Risk

“Starting in early 2025, the United States government announced additional tariffs on certain goods imported into the U.S. from numerous countries and multiple nations countered with reciprocal tariffs and other actions in response. While the final tariffs and other measures to be imposed, and their applicability to our business, remain uncertain, such action” · word for word

Foreign Exchange Risk

“For the three months ended March 31, 2026, approximately 47% of our revenue was denominated in foreign currencies.” · word for word

Disease Outbreak Risk

“Sales of our livestock products have in the past, and may in the future be, adversely affected by the outbreak of disease carried by animals.” · word for word

U.S. companion animal demand weakness due to price sensitivity and competition.

“Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products.” · word for word

Generic competition impacting key brands (Convenia, Cerenia).

“Impact of generic competition on the Convenia and Cerenia brands.” · word for word

Fiscal Year Alignment changes add complexity and one-time revenue boost.

“Operational changes made in connection with the company’s Fiscal Year Alignment contributed an estimated $100 million in revenue to the quarter.”

Relative TSR underperformance

“performance award units for the 2023-2025 cycle vested at 0% of target, reflecting Relative TSR performance at the 19th percentile of the S&P 500 Group” · word for word

Key product social media backlash

“The company's key OA pain medications, Librela (for dogs) and Solensia (for cats), experienced an 11 % operational decline globally. This was largely attributed to negative perceptions and reports of adverse side effects amplified on social media” · word for word

Indebtedness risk

“As of December 31, 2025, we had approximately $9.2 billion of total unsecured indebtedness outstanding related to our senior notes and convertible senior notes.” · word for word

Tax litigation risk

“In September 2024, the IRS issued a Revenue Agent Report related to the one-time mandatory deemed repatriation tax. ... we disagree with the IRS' position and will defend our position.” · word for word

Fiscal year alignment operational disruption

“In connection with the Expected Fiscal Year Alignment, revenue in the International segment for the reported fourth quarter of 2025 benefited from operational changes ... a trend that we do not expect to recur.” · word for word

Decline in mAb OA pain products (Librela, Solensia) partially offset by other growth.

“Sales of companion animal products decreased 1%. A decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs and Solensia for cats, was partially offset by growth in parasiticides.” · word for word

Potential dilution from conversion of notes; capped call transactions mitigate but do not eliminate.

“initial conversion rate will be 6.7476 shares of Zoetis’ common stock per $1,000 principal amount of Notes” · word for word

Dividend increase is modest and sustainable; no material risk.

“6% increase is in line with historical practice and cash flow generation.”

Decline in mAb products for OA pain (Librela, Solensia) impacting U.S. companion animal growth.

“Sales of the company's innovative companion animal products were flat for the quarter. Growth in the company's parasiticides portfolio... were offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain” · word for word

Tariff and trade policy risk

“Such actions may negatively impact demand and result in an increase in some product costs.” · word for word